Patents by Inventor Anthony E. Carpanzano
Anthony E. Carpanzano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10406106Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.Type: GrantFiled: November 21, 2018Date of Patent: September 10, 2019Assignee: ENDO PHARMACEUTICALS INC.Inventors: Anand R. Baichwal, Philip A. Goliber, Anthony E. Carpanzano, Thomas Sciascia, Donald Diehl, Brian Vogler, David Verbel, Stanley Au
-
Publication number: 20190117576Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.Type: ApplicationFiled: November 21, 2018Publication date: April 25, 2019Inventors: Anand R. BAICHWAL, Philip A. GOLIBER, Anthony E. CARPANZANO, Thomas SCIASCIA, Donald DIEHL, Brian VOGLER, David VERBEL, Stanley AU
-
Patent number: 10172798Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.Type: GrantFiled: July 24, 2017Date of Patent: January 8, 2019Assignee: Endo Pharmaceuticals Inc.Inventors: Anand R. Baichwal, Philip A. Goliber, Anthony E. Carpanzano, Thomas Sciascia, Donald Diehl, Brian Vogler, David Verbel, Stanley Au
-
Publication number: 20180042852Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.Type: ApplicationFiled: July 24, 2017Publication date: February 15, 2018Inventors: Anand R. BAICHWAL, Philip A. GOLIBER, Anthony E. CARPANZANO, Thomas SCIASCIA, Donald DIEHL, II, Brian VOGLER, David VERBEL, Stanley AU
-
Publication number: 20160263035Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.Type: ApplicationFiled: May 23, 2016Publication date: September 15, 2016Applicant: Endo Pharmaceuticals Inc.Inventors: Anand R. BAICHWAL, Philip A. Goliber, Anthony E. Carpanzano, Thomas Sciascia, Donald Diehl, Brian Vogler, David Verbel, Stanley Au
-
Patent number: 9351938Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.Type: GrantFiled: May 29, 2014Date of Patent: May 31, 2016Assignee: ENDO PHARMACEUTICALS INCInventors: Anand R. Baichwal, Philip A. Goliber, Anthony E. Carpanzano, Thomas Sciascia, Donald Diehl, II, Brian Vogler, David Verbel, Stanley Au
-
Patent number: 9186330Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.Type: GrantFiled: June 30, 2014Date of Patent: November 17, 2015Assignee: Endo Pharmaceuticals INC.Inventors: Anand R. Baichwal, Philip A. Goliber, Anthony E. Carpanzano, Thomas Sciascia, Donald Diehl, II, Brian Vogler
-
Publication number: 20140315937Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.Type: ApplicationFiled: June 30, 2014Publication date: October 23, 2014Inventors: Anand R. Baichwal, Philip A. Goliber, Anthony E. Carpanzano, Thomas Sciascia, Donald Diehl, II, Brian Vogler
-
Publication number: 20140271852Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.Type: ApplicationFiled: May 29, 2014Publication date: September 18, 2014Applicant: PENWEST PHARMACEUTICALS CO.Inventors: Anand R. BAICHWAL, Philip A. GOLIBER, Anthony E. CARPANZANO, Thomas SCIASCIA, Donald DIEHL, II, Brian VOGLER, David VERBEL, Stanley AU
-
Publication number: 20140199383Abstract: The present invention relates to transdermal dosage form (FIGS. 1-3) comprising at least one activating agent and at least one inactivating agent. The dosage form (FIGS. 1-3) releases the inactivating agent upon disruption of the dosage form (FIGS. 1-3) thereby preventing or hindering misuse of the active agent contained in the dosage form (FIGS. 1-3).Type: ApplicationFiled: January 21, 2014Publication date: July 17, 2014Applicant: PURDUE PHARMA L.P.Inventors: Lino Tavares, Bruce E. Reidenberg, Richard S. Sackler, Curtis Wright, Mark A. Alfonso, Benjamin Oshlack, James P. Cassidy, Anthony E. Carpanzano, Rampurna P. Gullapalli, Ihor Shevchuk
-
Patent number: 8771732Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.Type: GrantFiled: August 24, 2006Date of Patent: July 8, 2014Assignee: Endo Pharmaceuticals IncInventors: Anand R. Baichwal, Philip A. Goliber, Anthony E. Carpanzano, Thomas Sciascia, Donald Diehl, II, Brian Vogler
-
Patent number: 8765175Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.Type: GrantFiled: February 21, 2013Date of Patent: July 1, 2014Assignee: Endo Pharmaceuticals IncInventors: Anand R. Baichwal, Philip A. Goliber, Anthony E. Carpanzano, Thomas Sciascia, Donald Diehl, II, Brian Vogler, David Verbel, Stanley Au
-
Patent number: 8394812Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.Type: GrantFiled: May 23, 2008Date of Patent: March 12, 2013Assignee: Penwest Pharmaceuticals Co.Inventors: Anand R. Baichwal, Philip A. Goliber, Anthony E. Carpanzano, Thomas Sciascia, Donald Diehl, II, Brian Vogler, David Verbel, Stanley Au
-
Publication number: 20090030026Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.Type: ApplicationFiled: May 23, 2008Publication date: January 29, 2009Inventors: Anand R. Baichwal, Philip A. Goliber, Anthony E. Carpanzano, Thomas Sciascia, Donald Diehl, II, Brian Vogler, David Verbel, Stanley Au
-
Patent number: 7384653Abstract: The present invention provides an oral dosage form comprising a first composition and a second composition. The first composition comprises an effective amount of a therapeutic agent and the second composition comprises an effective amount of an adverse-effect agent. The adverse-effect agent is covered with a coating that is substantially insoluble in the gastrointestinal tract. In one embodiment, the adverse-effect agent is coated with an outer base-soluble layer and an inner acid-soluble layer. The therapeutic agent can be uncoated or can be coated with a coating having an outer acid-soluble layer and an inner base-soluble layer. The dosage form discourages administration of the therapeutic agent by other than oral administration.Type: GrantFiled: September 23, 2004Date of Patent: June 10, 2008Assignee: Purdue Pharma L.P.Inventors: Curtis Wright, IV, Anthony E. Carpanzano
-
Publication number: 20040241218Abstract: The present invention relates to transdermal dosage form (FIG. 1-3) comprising at least one activating agent and at least one inactivating agent. The dosage form (FIG. 1-3) releases the inactivating agent upon disruption of the dosage form (FIG. 1-3) thereby preventing or hindering misuse of the active agent contained in the dosage form (FIG. 1-3).Type: ApplicationFiled: November 20, 2003Publication date: December 2, 2004Inventors: Lino Tavares, Bruce E Reidenberg, Richard S Sackler, Curtis Wright, Mark A Alfonso, Benjamin Oshlack, James P Cassidy, Anthony E Carpanzano, Rampurna P Gullapalli, Ihor Shevchuk
-
Publication number: 20030044458Abstract: The present invention provides an oral dosage form comprising a first composition and a second composition. The first composition comprises an effective amount of a therapeutic agent and the second composition comprises an effective amount of an adverse-effect agent. The adverse-effect agent is covered with a coating that is substantially insoluble in the gastrointestinal tract. In one embodiment, the adverse-effect agent is coated with an outer base-soluble layer and an inner acid-soluble layer. The therapeutic agent can be uncoated or can be coated with a coating having an outer acid-soluble layer and an inner base-soluble layer. The dosage form discourages administration of the therapeutic agent by other than oral administration.Type: ApplicationFiled: August 1, 2002Publication date: March 6, 2003Inventors: Curtis Wright, Anthony E. Carpanzano
-
Patent number: 4996047Abstract: Disclosed are oral pharmaceutical preparations which comprise a pharmacologically active drug bound to small particles of an ion-exchange resin to provide a drug-resin complex having a drug content above a specified value. The drug-resin complex is subsequently coated with a water-permeable diffusion barrier coating that is insoluble in gastrointestinal fluids thereby providing a controllable sustained release of drug under conditions encountered in the gastrointestinal tract.Type: GrantFiled: November 2, 1988Date of Patent: February 26, 1991Assignee: Richardson-Vicks, Inc.Inventors: William J. Kelleher, Anthony E. Carpanzano
-
Patent number: RE45822Abstract: The present invention provides an oral dosage form comprising a first composition and a second composition. The first composition comprises an effective amount of a therapeutic agent and the second composition comprises an effective amount of an adverse-effect agent. The adverse-effect agent is covered with a coating that is substantially insoluble in the gastrointestinal tract. In one embodiment, the adverse-effect agent is coated with an outer base-soluble layer and an inner acid-soluble layer. The therapeutic agent can be uncoated or can be coated with a coating having an outer acid-soluble layer and an inner base-soluble layer. The dosage form discourages administration of the therapeutic agent by other than oral administration.Type: GrantFiled: October 28, 2013Date of Patent: December 22, 2015Assignee: Purdue Pharma L.P.Inventors: Curtis Wright, IV, Anthony E. Carpanzano